Erasca (ERAS) Net Equity Issued and Repurchased (2020 - 2026)

Erasca (ERAS) posted Net Equity Issued and Repurchased of $258.8 million for Q1 2026, up 248.16% on a QoQ basis from -$174.6 million in Q4 2024.

Erasca (ERAS) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends

Erasca's Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $258.8 million for Q1 2026.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $258.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200.0 million (changed N/A YoY) and the FY2024 annual result came in at $21.0 million, changed N/A from the prior year.
Net Equity Issued and Repurchased was $258.8 million for Q1 2026 at Erasca, up from -$174.6 million in the prior quarter.
Across five years, Net Equity Issued and Repurchased topped out at $258.8 million in Q1 2026 and bottomed at -$174.6 million in Q4 2024.
A 3-year average of $50.0 million and a median of $58.0 million in 2022 frame the typical range for Net Equity Issued and Repurchased.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	163.10 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	141.90 Mn
10	Erasca	5.89 Bn	5.89 Bn	-	258.75 Mn

Download Data